GYKI 46903

Drug Profile

GYKI 46903

Latest Information Update: 24 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Drug Research Institute
  • Class Antiemetics; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M3 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cognition disorders; Nausea and vomiting

Most Recent Events

  • 26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top